Press Release
G2GBio has the best experts in the field of innovative improved injectable drug development.
-
G2GBio, Raises KRW 21.8 Billion in Pre-IPO Funding, Accumulates KRW 58..G2GBio, Raises KRW 21.8 Billion in Pre-IPO Funding, Accumulates KRW 58 Billion in Total Investments,..
2023.11.17 -
Development of a one-month extended-release subcutaneous donepezil inj..Development of a one-month extended-release subcutaneous donepezil injection... "World's first...
2023.10.16 -
The Spectacular Rookie Venture Company The sustained-release post-oper..The Spectacular Rookie Venture CompanyThe sustained-release post-operative pain treatment has ..
2023.09.21 -
"G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development .."G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development Results at American Diabetes A..
2023.06.29 -
G2GBIO Signs Master Service Agreement with Global Pharmaceutical Compa..“G2GBIO Signs Master Service Agreement with Global Pharmaceutical Company for Microsphere Sustaine..
2023.04.26 -
G2GBio: "Positive Signal for Development of Monthly Donepezil (GB..G2GBio: "Positive Signal for Development of Monthly Donepezil (GB-5001) Formulation" ..
2023.04.17 -
G2GBIO, "Remarkable outcomes in non-clinical study for their Sema..G2GBIO, "Remarkable outcomes in non-clinical study for their Semaglutide microspheres"(Mon..
2023.04.11 -
G2GBio signs a Collaboration Agreement with a global pharmaceutical co..G2GBio signs a Collaboration Agreement with a global pharmaceutical company for long-acting diabetes..
2023.02.02